NCT02282371 - Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2014

Primary Completion Date

October 22, 2021

Study Completion Date

October 22, 2021

Conditions

Head and Neck Squamous Cell Cancer

Interventions

DRUG

Cetuximab

DRUG

BYL719

RADIATION

IMRT (Intensity-Modulated Radiation Therapy)

Trial Locations (6)

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Westchester, Harrison

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

Memorial Sloan Kettering Monmouth, Middletown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre